121 related articles for article (PubMed ID: 38807673)
1. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
2. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu LL; Skribek M; Harmenberg U; Gerling M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
[TBL] [Abstract][Full Text] [Related]
3. Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome.
Urasaki T; Ono M; Mochizuki T; Takeda K; Nishizawa A; Fukagawa E; Fujiwara M; Komai Y; Kitano S; Yuasa T; Yonese J; Takahashi S
Front Oncol; 2021; 11():681997. PubMed ID: 33996612
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.
Sackstein P; Zaemes J; Kim C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330765
[TBL] [Abstract][Full Text] [Related]
6. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.
Ohira J; Kawamoto M; Sugino Y; Kohara N
Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
[TBL] [Abstract][Full Text] [Related]
8. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
Front Immunol; 2022; 13():807050. PubMed ID: 35154124
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
Tsutsui T; Hata K; Kawaguchi M; Kobayashi H; Kakizaki Y; Miyashita Y
Thorac Cancer; 2023 Aug; 14(23):2310-2313. PubMed ID: 37381088
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
Ntwali F; Gilliaux Q; Honoré PM
Am J Case Rep; 2024 Apr; 25():e941835. PubMed ID: 38625840
[TBL] [Abstract][Full Text] [Related]
11. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.
Deng PB; Jiang J; Hu CP; Cao LM; Li M
World J Clin Cases; 2022 Feb; 10(5):1580-1585. PubMed ID: 35211595
[TBL] [Abstract][Full Text] [Related]
12. Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.
Zhou Y; Zheng GH; Li N; Liu JJ; Wang XH; Li YF
Immunotherapy; 2023 Jun; 15(9):641-645. PubMed ID: 37139989
[TBL] [Abstract][Full Text] [Related]
13. Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Inoue Y; Fujino T; Chinen S; Niiyama-Uchibori Y; Ide D; Kawata M; Hashimoto K; Takimoto-Shimomura T; Nakayama A; Tsukamoto T; Mizutani S; Shimura Y; Hirano S; Kuroda J
Cureus; 2023 May; 15(5):e38905. PubMed ID: 37303362
[TBL] [Abstract][Full Text] [Related]
14. Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction: A Case Report.
Nakashima K; Kitani K; Kono K; Yoshihara K; Kawakado K; Kobayashi M; Okuno T; Amano Y; Tsubata Y; Isobe T
Intern Med; 2023 Dec; ():. PubMed ID: 38104995
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.
Ceschi A; Noseda R; Palin K; Verhamme K
Front Pharmacol; 2020; 11():557. PubMed ID: 32425791
[TBL] [Abstract][Full Text] [Related]
16. Double systemic cytokine release syndrome following sequential infusion of anti-CD22 and anti-CD19 chimeric antigen receptor T cells after autologous hematopoietic stem cell transplantation for a central diffuse large B-cell lymphoma patient: A case report and literature review.
Zheng J; Xiao Y; Wu XQ; Xiao QZ; Feng C; Gao KB
Front Immunol; 2023; 14():1098815. PubMed ID: 36798130
[TBL] [Abstract][Full Text] [Related]
17. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.
Zhang Y; Wen X; OuYang Y; Hu Y; Fang X; Zhang J; Yuan Y
Heliyon; 2024 Jan; 10(2):e24380. PubMed ID: 38293388
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
19. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
[TBL] [Abstract][Full Text] [Related]
20. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
